Add Presentation to Slide Tray Presentation:
Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis
Potential Harms of rhGH Treatment to Patients With CF: Cancer Risk (1)
Patients with CF have an elevated risk of cancer of the digestive tract. Because patients with CF are living longer, the impact of rhGH treatment on cancer risk is a concern.
Keywords: cancer | risk | gastrointestinal | digestive | cystic fibrosis | CF | rhGH | recombinant human growth hormone | human growth hormone | HGH
- Neglia JP, Wielinshi CL, Warwick WJ. Cancer risk among patient with cystic fibrosis. J Pediatr 1991;119:764-6.
- Neglia JP, FitzSimmons SC, Maisonneuve P, et al, for the Cystic Fibrosis and Cancer Study Group. The risk of cancer among patients with cystic fibrosis. N Engl J Med 1995; 332:494-9.
- Maisonneuve P, FitzSimmons SC, Neglia JP, et al. Cancer risk in nontransplanted and transplanted cystic fibrosis patients: a 10-year study. J Natl Cancer Inst 2003;95:381-7.
- Phung OJ, Coleman CI, Baker EL, et al. Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis. AHRQ Comparative Effectiveness Review No. 23 (Prepared by University of Connecticut-Hartford Hospital Evidence-based Practice Center under Contract No. 290-2007-10067-I). Rockville, MD: Agency for Healthcare Research and Quality; October 2010. AHRQ Publication No. 11-EHC003-EF.
Your slide tray is being processed.